Phase 2
Completed N=66
Oxytocin for Couples Conflict Resolution
Substance Misuse · Interpersonal Conflict · Neuroendocrine Reactivity
Source: ClinicalTrials.gov NCT02941692 ↗
Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Change in Frequency of Distress Maintaining Attributions — .81; -.48 distress maintaining attributions
Summary
Oxytocin is a promising new medication found to have positive effects on prosocial behavior, reduce negative affect such as fear and anxiety, and reduce stress-induced addictive behaviors. This study aims to investigate the extent to which a 40 IU dose of intranasal oxytocin improves couples' conflict resolution skills and subjective, physiological, and neuroendocrine responses to conflict. Conflict resolution discussions will take place in the laboratory and will be videotaped.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Frequency of Distress Maintaining Attributions |
.81; -.48 | — |
| SECONDARY Change in Salivary Cortisol (μg/dL) |
.28; .30; .25; .29; .18; .21 | — |
Eligibility Criteria
Inclusion Criteria
- 18-65 years of age
- both partners are willing to participate, and
- at least one partner has engaged in hazardous drinking (i.e. 4 or more drinks for women, 6 or more for men) or illicit drug use during the past 60 days
Exclusion Criteria
- pregnancy for women
- current psychotic or bipolar disorders
- active suicidal or homicidal ideation and intent
- subjects who would present a serious suicide risk, such as those with severe depression, or who are likely to require hospitalization during the course of the study
- severe, unilateral intimate partner violence in the past year
- BMI greater than 39.
Data sourced from ClinicalTrials.gov (NCT02941692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.